Stocks / MRNA

MRNA stock forecast

MODERNA INC · Healthcare · Biotechnology

The model's rating

Greatly Underperform

MRNA is rated Greatly Underperform as of November 18, 2026: its medium-term return forecast is in the bottom fifth of the stocks the model scores.

Changed from Underperform on November 4, 2026.

Premium adds the numeric score behind this label, the medium-term return forecast, and today's full Upfront Picks.

Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.

MRNA is not among the 20 largest holdings published for 2026 Q4. See the portfolio

MRNA against the S&P 500

PeriodMRNAS&P 500 (SPY)
1 month-13.3%-4.7%
3 months+12.9%-4.8%
Year to date+567.3%+7.9%
1 year+689.7%+11.8%

Total return, dividends included.

Key numbers

Price$196.79
Market cap79.63 Billion
P/E (trailing 12 months)-27.8
P/S (trailing 12 months)31.5
P/B (latest quarter)15.0
Gross margin28.0%
Net profit margin-110.5%
Return on equity-37.6%
Beta2.4

As of November 6, 2026.

MRNA and its closest peers

StockCompanyMarket capModel rating
REGN REGENERON PHARMACEUTICALS INC 97.81 Billion Outperform REGN vs MRNA
INCY INCYTE CORP 24.01 Billion Greatly Outperform MRNA vs INCY
VRTX VERTEX PHARMACEUTICALS INC 136.01 Billion Outperform VRTX vs MRNA
TECH BIO-TECHNE CORP 11.43 Billion Underperform MRNA vs TECH

Questions

What does the Upfront Investment model say about MRNA?

The model rates MODERNA INC (MRNA) "Greatly Underperform" as of November 18, 2026, which means its medium-term return forecast is in the bottom fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.

How is the MRNA rating produced?

A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.

Is MRNA in the Upfront Investment model portfolio?

MRNA is not among the 20 largest holdings published for 2026 Q4.

The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.